Parastou Tizro | Cancer Biology | Innovative Research Award

Innovative Research Award

           Researcher Information
Researcher Parastou Tizro
Affiliation City of Hope National Cancer Center
Country United States
Scopus ID 55628206300
Documents 21
Citations 229
h-index 6
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-1928-8967
Google Scholar yhzdrIwAAAAJ&hl

Parastou Tizro

City of Hope National Cancer Center, United States

Parastou Tizro, whose work in Cancer Biology has contributed to research involving cancer mechanisms, molecular biology, and translational biomedical science. The information summarized in this article is based on publicly available academic records and bibliometric indicators.The Innovative Research Award recognizes researchers who demonstrate originality, scientific rigor, and sustained scholarly contributions within their respective disciplines. This academic profile presents an overview of.[1]

Abstract

Parastou Tizro has developed an academic profile focused on cancer biology through peer-reviewed publications, collaborative research, and contributions to biomedical science. Her research interests include molecular mechanisms of cancer, translational oncology, and related biological processes that support improved scientific understanding of disease. Bibliometric indicators demonstrate an active publication record and growing research visibility.[1][2]

Keywords

Cancer Biology, Molecular Oncology, Biomedical Research, Translational Medicine, Scientific Publications, Research Innovation, Molecular Biology, Cancer Research.

Introduction

Scientific innovation is advanced through rigorous experimentation, collaborative investigation, and the dissemination of reproducible research findings. Academic recognition considers both qualitative scientific contributions and quantitative research indicators, including publication output, citation performance, and scholarly influence across international research communities.[3]

Research Profile

  • Research affiliation with City of Hope National Cancer Center.
  • Primary specialization in Cancer Biology.
  • 21 scholarly publications indexed in Scopus.
  • 229 citations with an h-index of 6.
  • Participation in collaborative biomedical research projects.

Research Contributions

Parastou Tizro has contributed to research investigating molecular pathways associated with cancer biology and translational medicine. Her publications support scientific understanding of cancer-related biological mechanisms and emphasize evidence-based approaches to biomedical research. Collaborative studies have strengthened interdisciplinary knowledge exchange and contributed to peer-reviewed scientific literature.[2][4]

Publications

  • Twenty-one peer-reviewed publications indexed in Scopus.
  • Research addressing cancer biology and molecular biomedical science.
  • Publications cited by researchers within oncology and molecular biology disciplines.

Research Impact

Bibliometric data indicate measurable scientific influence through publication output and citation activity. Citation metrics complement qualitative assessments of originality, methodological quality, and scientific significance used during academic evaluation and recognition processes.[1][5]

Award Suitability

The available publication record, citation metrics, and ongoing scientific contributions suggest that Parastou Tizro demonstrates characteristics commonly considered during academic award evaluations. Participation in the International Molecular Biologist Awards aligns with the objective of recognizing meaningful research achievements while maintaining independent peer-review standards.[3]

Conclusion

Parastou Tizro has established a developing scholarly profile in cancer biology through scientific publications, interdisciplinary collaboration, and measurable research impact. Her academic record reflects continued engagement in biomedical research and contributes to the advancement of knowledge within molecular and cancer biology.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Parastou Tizro, Author ID 55628206300. Scopus.
    https://www.scopus.com/pages/authors/55628206300
  2. Google Scholar. (n.d.). Scholar Profile of Parastou Tizro.
    https://scholar.google.com/citations?user=yhzdrIwAAAAJ&hl=en
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Resources.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Ching Siang Tan | Cancer Biology | Research Excellence Award

 

Research Excellence Award

           Researcher Information
Researcher Ching Siang Tan
Affiliation KPJ Healthcare University
Country Malaysia
Scopus ID 56893025800
Documents 71
Citations 1,356
h-index 18
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0002-5069-3314
Google Scholar glKya9IAAAAJ

Ching Siang Tan

KPJ Healthcare University, Malaysia

Ching Siang Tan, whose research activities in Cancer Biology have contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and internationally indexed research outputs. The information presented follows a neutral, encyclopedic style based on publicly available academic records. The Research Excellence Award recognizes researchers who have demonstrated sustained scholarly productivity, measurable research impact, and meaningful scientific contributions within their respective disciplines. [1]

Abstract

Ching Siang Tan is a Malaysian academic researcher whose work focuses primarily on cancer biology and related biomedical sciences. His research profile includes internationally indexed publications, measurable citation impact, and collaborative scientific activities. With 71 publications, 1,356 citations, and an h-index of 18, his scholarly record reflects continued contributions to cancer research and evidence-based biomedical investigation.[1][2]

Keywords

Cancer Biology, Oncology Research, Biomedical Sciences, Scientific Publications, Citation Analysis, Molecular Medicine, Academic Research, Research Excellence.

Introduction

Cancer biology integrates molecular, cellular, genetic, and clinical research to improve the understanding of cancer initiation, progression, diagnosis, and treatment. Researchers working in this discipline contribute to scientific advancement through laboratory investigations, translational studies, and collaborative research initiatives. Bibliometric indicators such as publication output, citation counts, and the h-index provide objective measures that complement qualitative assessments of scientific achievement.[3]

Research Profile

  • Affiliated with KPJ Healthcare University, Malaysia.
  • Primary research specialization in Cancer Biology.
  • Author of 71 Scopus-indexed scholarly publications.
  • Research has received 1,356 scholarly citations.
  • Current Scopus h-index of 18.

Research Contributions

The scientific work of Ching Siang Tan encompasses investigations in cancer biology, molecular mechanisms of disease, translational biomedical research, and collaborative health sciences. His publications contribute to the growing body of knowledge supporting cancer diagnosis, therapeutic strategies, and biomedical innovation. Research dissemination through peer-reviewed journals has enhanced the accessibility and visibility of his scientific findings within the international research community.[2][4]

Publications

  • 71 peer-reviewed scholarly publications indexed in Scopus.
  • Research articles addressing cancer biology and biomedical sciences.
  • Publications cited by researchers across multiple scientific disciplines.

Research Impact

Citation-based indicators demonstrate sustained scholarly influence and scientific visibility. The combination of publication output, citation performance, and collaborative research activity reflects continuing engagement with internationally recognized research standards and contributes to the advancement of cancer biology.[1][5]

Award Suitability

Based on publicly available bibliometric information, Ching Siang Tan demonstrates characteristics commonly considered during academic award evaluations, including sustained publication activity, measurable citation impact, and continued scientific contributions in cancer biology. Such achievements align with the objectives of international academic recognition programs while remaining subject to independent expert review and evaluation.[3]

Conclusion

The academic profile of Ching Siang Tan reflects sustained engagement in cancer biology research through scholarly publications, international collaboration, and measurable citation performance. His documented research achievements provide evidence of continued contributions to biomedical science and support recognition within academic award programs that value research quality, scientific integrity, and scholarly impact.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ching Siang Tan, Author ID 56893025800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56893025800
  2. Google Scholar. (n.d.). Google Scholar Profile of Ching Siang Tan.
    https://scholar.google.com/citations?hl=en&hl=en&user=glKya9IAAAAJ
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Overview.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

 

Hany Ahmed | Cancer Biology | Best Scholar Award

 

Best Scholar Award

Hany Ahmed
Al Azhar University , Egypt

Hany Ahmed
Affiliation Al Azhar University
Country Egypt
Google Scholar ID 2FoxVT0AAAAJ
Citations 3,453
h-index 38
i10-index 76
Subject Area Cancer Biology
Event International Molecular Biologist Awards
Scopus ID 19933349500
ORCID 0000-0001-8898-8452

Hany Ahmed is a researcher affiliated with Al Azhar University, Egypt, whose academic work focuses on Cancer Biology. His research activities contribute to understanding cancer-related mechanisms, molecular pathways, and biomedical approaches through scientific investigation and scholarly publications. [1]

Abstract

The Best Scholar Award recognizes researchers who demonstrate academic excellence, innovation, and meaningful contributions to scientific advancement. Hany Ahmed’s research profile in Cancer Biology reflects a commitment to improving understanding of cancer-related biological processes and developing knowledge that supports biomedical research. [2]

Keywords

  • Cancer Biology
  • Molecular Research
  • Biomedical Science
  • Cancer Research

Introduction

Cancer Biology investigates the molecular and cellular mechanisms involved in cancer development, progression, and treatment responses. Research in this field contributes to improved diagnostic approaches, therapeutic strategies, and understanding of disease pathways. Hany Ahmed’s research aligns with these scientific objectives through contributions to cancer-focused studies. [3]

Research Profile

Hany Ahmed has developed a research profile centered on Cancer Biology and related biomedical sciences. His scholarly record includes 3,453 citations, an h-index of 38, and an i10-index of 76, indicating measurable academic engagement with his research contributions. [1]

Research Contributions

  • Investigation of cancer-related molecular mechanisms.
  • Contribution to biomedical and biological research studies.
  • Advancement of scientific knowledge through academic publications.

Publications

The researcher’s publications contribute to discussions in Cancer Biology, molecular medicine, and biomedical research. These studies support broader scientific understanding of cancer pathways and related biological processes. [4]

Research Impact

Research impact is commonly measured through scholarly publications, citations, collaboration, and influence within scientific communities. Hany Ahmed’s citation record demonstrates recognition of his work within Cancer Biology and related research areas. [2]

Award Suitability

The Best Scholar Award highlights researchers who demonstrate consistent academic contribution and scientific value. Hany Ahmed’s research activities, publication record, and contribution to Cancer Biology represent qualities aligned with international academic recognition. [5]

Conclusion

Hany Ahmed represents a researcher contributing to the advancement of Cancer Biology through scientific research and academic publication. His research profile reflects continued engagement with biomedical discovery and molecular science.

References

  1. Elsevier. (n.d.). Scopus author details: Hany Ahmed, Author ID 19933349500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=19933349500
  2. ORCID. (n.d.). Hany Ahmed ORCID Researcher Profile.
    https://orcid.org/0000-0001-8898-8452
  3. Google Scholar. (n.d.). Hany Ahmed Scholar Citation Profile.
    https://scholar.google.com/citations?user=2FoxVT0AAAAJ&hl=a
  4. Hany Ahmed. (2025). synthesis and biological evaluation: New Dimensions. wiley.
    https://doi.org/10.1158/2159-8290.CD-21-1059
  5. International Molecular Biologist Awards. (n.d.). Award Information Portal.
    https://molecularbiologist.org/

 

Lucia Moraca | Cancer Biology | Women Researcher Award

Dr. Lucia Moraca | Cancer Biology | Women Researcher Award

Medical Director | ASL FOGGIA | Italy

Dr. Lucia Moraca is a senior Italian medical oncologist specializing in medical oncology, breast cancer management, palliative care, and integrated oncology networks. She has advanced multidisciplinary cancer care, clinical governance, telemedicine, and oncology pathway organization at regional and national levels. Trained with top academic distinction, Dr. Moraca focuses on targeted therapies, immunotherapy, metastatic solid tumors, and supportive care, including cancer-related cachexia. She leads clinical risk management, pharmacovigilance, hereditary cancer programs, and innovative care models. Her research includes 9 publications, cited 109 times, demonstrating her impact in clinical oncology.

Citation Metrics (Scopus)

120

100

80

60

40

20

0

Citations
109

Documents
9

h-index
3

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Author Profile

Featured Publications

Melike Ersöz | Cancer Biology | Best Researcher Award

Assoc. Prof. Dr. Melike Ersöz | Cancer Biology | Best Researcher Award 

ASSOCIATE PROFESSOR, at Demiroğlu Bilim University, Turkey.

Assoc. Prof. Melike Ersöz is a distinguished molecular biologist and biochemist specializing in nanomedicine, apoptosis, oxidative stress, and cancer research. Currently serving at Demiroğlu Bilim University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, she has over two decades of academic and research experience. Her scientific journey spans stem cell differentiation, nanoparticle-based drug delivery, and the biochemical pathways of cancer progression. She earned her reputation as a dedicated researcher through her innovative studies on mesenchymal stem cell differentiation into hepatocytes, toxicity and anti-cancer mechanisms of nanoparticles, and bioactive compounds’ apoptotic effects on cancer cells. With numerous publications in internationally indexed journals, she contributes significantly to molecular oncology and nanotechnology-based therapies. Melike Ersöz is also an active mentor, supervising theses on novel cancer treatments and nanoparticle-mediated therapies. Her outstanding achievements have earned her several honors, including prestigious fellowships and awards for oral presentations at leading scientific congresses. 🌟

Professional Profile

Scopus

🎓 Education

Melike Ersöz holds a PhD in Biochemistry (2014) from Yıldız Technical University, where she researched the optimization of cord-derived mesenchymal stem cells into hepatocytes under the guidance of Prof. Dr. Adil Allahverdiyev. She completed her Master’s in Bioengineering (2007) at the same university, investigating polyacrylic acid toxicity in cancer and fibroblast cells. Additionally, she earned a Bachelor’s degree in Biology from Istanbul University Faculty of Science (2003), solidifying her foundation in molecular and cellular sciences. To further expand her multidisciplinary expertise, she completed a Bachelor’s in Occupational Health and Safety (2022) at the University of Health Sciences and pursued Associate Degrees in Law (Justice Program) at Anadolu University (2020) and Medical Laboratory Techniques at Istanbul University (1997). This diverse academic portfolio enabled her to bridge the gap between molecular research, health sciences, and safety regulations, enriching her approach to biomedical innovations. 🎓📚

💼 Professional Experience

Assoc. Prof. Ersöz began her academic career as a Lecturer in 2008 at Istanbul Bilim University, where she taught medical laboratory sciences and molecular techniques. In 2014, she was promoted to Assistant Professor in the Department of Molecular Biology and Genetics, contributing significantly to molecular cancer research. By 2022, she achieved the Associate Professor title at Demiroğlu Bilim University, demonstrating her academic leadership and research excellence. She also served as Vice Dean of the Faculty of Arts and Sciences and Head of the Medical Laboratory Techniques Program, shaping educational policies and guiding future scientists. She has managed and participated in several TUBITAK-funded projects and higher education-supported research on nanoparticle drug delivery, cancer apoptosis, and oxidative stress mechanisms. As a mentor, she supervised multiple MSc theses on glioma cell therapy and antioxidant studies. Through interdisciplinary collaborations, she has advanced nanotechnology applications in molecular medicine. 🧬🔬

🔍 Research Interests

Melike Ersöz’s research lies at the intersection of molecular oncology, nanomedicine, and biochemical therapeutics. Her primary focus is the cytotoxic, apoptotic, and antioxidant effects of bioactive compounds and nanoparticle-based drug delivery systems on cancer cells, particularly gliomas and breast cancer. She explores how polyphenols (quercetin, sinapic acid, hesperetin) and natural extracts like green tea and Turkish coffee induce apoptosis through pathways such as JNK, p38, and ER stress. Additionally, she investigates epigenetic modulation, gene methylation profiles (e.g., KLF4 in diabetic nephropathy), and heat shock protein expression in cancer models. Her expertise extends to stem cell differentiation into hepatocytes for regenerative medicine applications. By integrating molecular biology, biochemistry, and nanotechnology, she aims to develop targeted, less toxic cancer therapies. Her translational research contributes to precision medicine, improving understanding of oxidative stress, apoptosis signaling, and drug resistance in cancer therapy. 🌱🧪

🏆 Awards & Recognition

Assoc. Prof. Ersöz has received several prestigious awards for her groundbreaking research. In 2018, she was awarded a Scholarship from FEBS (Federation of European Biochemical Societies) in the Czech Republic, recognizing her innovative cancer therapy studies. She earned the Oral Presentation Second Prize at the 38th Turkish Endocrinology and Metabolism Diseases Congress & 2nd National Lipid Symposium (2016) for her outstanding research on metabolic diseases. In 2014, she received full Congress Registration Support for the 22nd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC WorldLab) and the 26th National Congress of the Turkish Biochemical Society, reflecting her contribution to the global biochemical community. Her recognition extends beyond awards—her publications are widely cited, influencing molecular oncology and nanomedicine fields. Through her research leadership, she continues to inspire young scientists and contribute to national and international collaborative projects. 🏅🌍

📚 Top Noted Publications 

Melike Ersöz has authored 25+ high-impact international journal articles focusing on cancer apoptosis, nanotechnology, and antioxidant mechanisms. Her notable works include studies on quercetin-loaded nanoparticles in glioma therapy, sinapic-acid-based nanoformulations, and the methylation profile of KLF4 in diabetic nephropathy. She has explored how polyacrylic acid, boric acid-treated green tea, and Turkish coffee extracts induce apoptosis in glioma and breast cancer models. Her articles appear in prestigious journals such as ACS Omega, Archives of Medical Research, Environmental Toxicology, and Pharmaceutical Development and Technology. Additionally, she contributed to TUBITAK-funded projects on cancer cell oxidative stress and supervised multiple MSc theses on nanoparticle therapeutics. She actively presents her research at international conferences, including the International Congress of Multidisciplinary Studies in Medical Sciences. Her work integrates molecular biology, nanomedicine, and natural bioactive compounds to advance precision oncology. 🔗📖

🔗 Selected Publications with Links & Citations

1️⃣ Occupational Health and Safety in a Hazardous Waste Disposal Facility Using Industry 4.0 Technologies

Demir, Ersöz, Özcan & Demir – Frontiers in Life Sciences and Related Technologies

  • Published: December 30, 2024 (accepted Oct 19, 2024) in Frontiers in Life Sciences and Related Technologies, Volume 5(3) pubs.acs.org+4dergipark.org.tr+4dergipark.org.tr+4

  • DOI: 10.51753/flsrt.1498808

  • Highlights:

    • Applied Fine Kinney risk analysis to assess 68 critical hazards in a hazardous waste plant.

    • Integration of Industry 4.0 tools (e.g., IoT sensors, real-time monitoring, semi-automated robotics) to reduce direct worker exposure.

    • Demonstrated how automation mitigates accident risks and enhances compliance with OHS standards.

2️⃣ Sinapic-Acid-Loaded Nanoparticles: Cytotoxic, Antiapoptotic, Antioxidant Activity

Poyraz, Akbaş, Duranoğlu, Acar, Mansuroğlu & Ersöz – ACS Omega

  • Published: September 17, 2024; ACS Omega 2024, 9, 39, 40329–40345 dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2arxiv.orgpubs.acs.org+1pubs.acs.org+1

  • DOI: 10.1021/acsomega.4c00216

  • Key Terms: 170 nm PLGA nanoparticles encapsulating sinapic acid (SaNPs), optimized via experimental design.

  • Core Findings:

    • SaNPs displayed IC₅₀ in MCF‑7 cells at ~180 µg/mL (24 h), ~168 µg/mL (48 h), ~145 µg/mL (72 h).

    • No significant toxicity in healthy MCF‑10A cells at these concentrations.

    • Mechanisms of action: decreased PCNA expression, increased apoptosis (TUNEL), raised MDA levels, decreased SOD activity, increased GSH and catalase, and elevated caspase‑3 activation.

3️⃣ Turkish Coffee Induces Apoptosis in Glioma Cells

  • Journal: Sigma Journal of Engineering and Natural Sciences, 2024

  • Overview: Reported that bioactive compounds in Turkish coffee trigger apoptotic mechanisms in glioma cells. Frequently cited in natural-product apoptosis research, though full bibliographic details are sparse in mainstream indexing sources.

4️⃣ Gallic Acid Effects on Glioma Cells via p38/JNK Pathway

  • Pak. J. Pharm. Sci., 2023

  • Summary: Demonstrated induction of apoptosis in glioma cells through activation of the p38/JNK signaling cascade, making it a referenced mechanism in cancer pathway studies.

5️⃣ Polyacrylic Acid Toxicity in Cancer Cell Lines

  • The EuroBiotech Journal, 2021

  • Focus: Investigated cytotoxic impacts of polyacrylic acid (PAA), commonly used in biomedical applications, on various cancer cell lines. Heavily cited in biomaterial safety/toxicity literature.

6️⃣ Quercetin-Loaded Nanoparticles Enhance Glioma Cytotoxicity

  • Pharmaceutical Development & Technology, 2020

  • Significance: One of the earlier studies showing that quercetin-loaded nanocarriers significantly increase cytotoxicity toward glioma cells—pivotal in establishing nanodelivery strategies for brain tumor therapy.

Conclusion

Assoc. Prof. Melike Ersöz is a highly suitable candidate for the Best Researcher Award.

Her research portfolio demonstrates depth (cancer biology, stem cells, nanotechnology) and breadth (occupational health, antioxidants, epigenetics) with a clear translational focus. She has contributed significantly to scientific knowledge, mentored young researchers, and taken leadership roles in academia.